drugset / Trial / NCT02912377
Immunogenicity and Pharmacodynamic of B12019 and Neulasta® in Healthy Subjects
RandomizedCrossoverTriple-blindTreatment
Summary
Multiple-doses, randomised, double-blind, three-periods, two-sequences crossover study to assess the immunogenicity and pharmacodynamic comparability of a biosimilar pegfilgrastim (B12019) and the reference product Neulasta® in healthy subjects
Timeline
- Start
- 2016-09
- Primary completion
- 2017-05
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegfilgrastim | Protein / enzyme biologic | — | — |
Indications
No indication recorded.